Literature DB >> 11337556

Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.

J S Lewis1, T L Sharp, R Laforest, Y Fujibayashi, M J Welch.   

Abstract

UNLABELLED: We showed previously that, in vitro, copper-diacetyl-bis(N(4)-methylthiosemicarbazone) (Cu-ATSM) uptake is dependent on the oxygen concentration (pO2). We also showed that, in vivo, Cu-ATSM uptake is heterogeneous in animal tumors known to contain hypoxic fractions. This study was undertaken to confirm the pO2 dependence of this selective uptake in vivo by correlating Cu-ATSM uptake with measured tumor pO2.
METHODS: Experiments were performed with the 9L gliosarcoma rat model using a needle oxygen electrode to measure tissue pO2. Using PET and electronic autoradiography, Cu-ATSM uptake was measured in tumor tissue under various pO2 levels. The oxygen concentration within implanted tumors was manipulated by chemical means or by altering the inhaled oxygen content.
RESULTS: A good correlation between low pO2 and high Cu-ATSM accumulation was observed. Hydralazine administration in animals caused a decrease in the average tumor pO2 from 28.61 +/- 8.74 mm Hg to 20.81 +/- 7.54 mm Hg in untreated control animals breathing atmospheric oxygen. It also caused the tumor uptake of Cu-ATSM to increase by 35%. Conversely, in animals breathing 100% oxygen, the average tumor pO2 increased to 45.88 +/-15.9 mm Hg, and the tumor uptake of Cu-ATSM decreased to 48% of that of the control animals. PET of animals treated in a similar fashion yielded time-activity curves showing significantly higher retention of the tracer in hypoxic tissues than in oxygenated tissues.
CONCLUSION: These data confirm that Cu-ATSM uptake in tissues in vivo is dependent on the tissue pO2, and that significantly greater uptake and retention occur in hypoxic tumor tissue. Therefore, the possible use of Cu-ATSM PET as a prognostic indicator in the management of cancer is further validated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337556

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  56 in total

Review 1.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.

Authors:  Keisha C McCall; John L Humm; Rachel Bartlett; Megan Reese; Sean Carlin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-23       Impact factor: 7.038

3.  PET/MRI of Hypoxic Atherosclerosis Using 64Cu-ATSM in a Rabbit Model.

Authors:  Xingyu Nie; Richard Laforest; Andrew Elvington; Gwendalyn J Randolph; Jie Zheng; Tom Voller; Dana R Abendschein; Suzanne E Lapi; Pamela K Woodard
Journal:  J Nucl Med       Date:  2016-07-07       Impact factor: 10.057

Review 4.  Nuclear imaging of molecular processes in cancer.

Authors:  Rafael Torres Martin de Rosales; Erik Arstad; Philip J Blower
Journal:  Target Oncol       Date:  2009-09-25       Impact factor: 4.493

5.  Towards new horizons in brain PET.

Authors:  Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06       Impact factor: 9.236

Review 6.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 7.  Assessing tumor hypoxia by positron emission tomography with Cu-ATSM.

Authors:  J P Holland; J S Lewis; F Dehdashti
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-04       Impact factor: 2.346

8.  Copper and zinc bis(thiosemicarbazonato) complexes with a fluorescent tag: synthesis, radiolabelling with copper-64, cell uptake and fluorescence studies.

Authors:  SinChun Lim; Katherine A Price; Siow-Feng Chong; Brett M Paterson; Aphrodite Caragounis; Kevin J Barnham; Peter J Crouch; Josephine M Peach; Jonathan R Dilworth; Anthony R White; Paul S Donnelly
Journal:  J Biol Inorg Chem       Date:  2009-09-22       Impact factor: 3.358

Review 9.  Tumor hypoxia: a new PET imaging biomarker in clinical oncology.

Authors:  Nagara Tamaki; Kenji Hirata
Journal:  Int J Clin Oncol       Date:  2015-11-14       Impact factor: 3.402

10.  Comparison of Helzel and OxyLite systems in the measurements of tumor partial oxygen pressure (pO2).

Authors:  Bixiu Wen; Muneyasu Urano; John L Humm; Venkatraman E Seshan; Gloria C Li; C Clifton Ling
Journal:  Radiat Res       Date:  2008-01       Impact factor: 2.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.